Farxiga

Drug Overview
Product Profiles
Farxiga : Diabetic nephropathy
Farxiga : Diabetes type 1
Farxiga : Chronic heart failure (CHF)
Farxiga : Diabetes type 2

Figure 1: The authors drug assessment summary of Farxiga for diabetic nephropathy
Figure 2: The authors drug assessment summary of Farxiga for diabetic nephropathy
Figure 3: Farxiga sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Farxiga for type 1 diabetes – SWOT analysis
Figure 5: The authors drug assessment of Farxiga in type 1 diabetes
Figure 6: The authors drug assessment of Farxiga in type 1 diabetes
Figure 7: Farxiga for chronic heart failure – SWOT analysis
Figure 8: The authors drug assessment summary of Farxiga for chronic heart failure
Figure 9: The authors drug assessment summary of Farxiga for chronic heart failure
Figure 10: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 11: Farxiga for type 2 diabetes – SWOT analysis
Figure 12: The authors drug assessment of Farxiga
Figure 13: The authors drug assessment scorecard for Farxiga compared to Januvia
Figure 14: Farxiga sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
Figure 15: Xigduo sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25

Table 1: Farxiga drug profile
Table 2: Farxiga Phase III trial in chronic kidney disease, including diabetic nephropathy
Table 3: Farxiga Phase II/III trial on UACR and glycemic control in diabetic nephropathy
Table 4: Farxiga for diabetic nephropathy – SWOT analysis
Table 5: Farxiga drug profile
Table 6: Farxiga late-phase trials in type 1 diabetes
Table 7: Farxiga drug profile
Table 8: Farxiga Phase III trials in chronic heart failure
Table 9: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 10: Farxiga franchise products
Table 11: Farxiga drug profile
Table 12: Xigduo drug profile
Table 13: Overview of pivotal trial data for Farxiga in diabetes
Table 14: Key planned and ongoing Phase III clinical trials for Farxiga in diabetes
Table 15: Farxiga sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 16: Xigduo sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25